(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 February 2008 (07.02.2008)

PCT

(10) International Publication Number
WO 2008/016838 A1

(51) International Patent Classification:
A61Q 17/04 (2006.01) *A61K 8/44* (2006.01)
A61Q 19/08 (2006.01) *A61K 8/64* (2006.01)
A61K 8/97 (2006.01) *A61K 8/63* (2006.01)
A61K 8/55 (2006.01) *A61K 8/73* (2006.01)
A61K 8/67 (2006.01) *A61K 8/34* (2006.01)
A61K 8/68 (2006.01)

(21) International Application Number:
PCT/US2007/074545

(22) International Filing Date: 27 July 2007 (27.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/497,152 31 July 2006 (31.07.2006) US
11/617,890 29 December 2006 (29.12.2006) US

(71) Applicant *(for all designated States except US)*: **ACCESS BUSINESS GROUP INTERNATIONAL LLC** [US/US]; 7575 Fulton Street East, Ada, MI 49355 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ZIMMERMAN, Amy, C.** [US/US]; 3018 Woodsboro Drive Ne, Grand Rapids, MI 49525-3055 (US). **DEPPA, Debra, J.** [US/US]; 6221 Patagonia Drive, Grand Rapids, MI 49546 (US). **O'TOOLE, Deborah, A.** [US/US]; 95 Holiday Drive, Ionia, MI 48846 (US). **MAYNE, James, R.** [US/US]; 11443 Boulder Drive East, Apt. 107, Lowell, MI 49331 (US).

(74) Agent: **NICHOLS, G., Peter**; Brinks Hofer Gilson & Lione, P.o. Box 10087, Chicago, IL 60610 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

WO 2008/016838 A1

(54) Title: TOPICAL SKIN COMPOSITIONS, THEIR PREPARATION AND THEIR USE

(57) Abstract: Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to inhibit those mechanisms. The compositions and methods are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. Thus, the compositions according to the invention improve barrier function, inhibit elastase and collagenase, and/or promote synthesis of collagen and elastin.

TOPICAL SKIN COMPOSITIONS, THEIR PREPARATION, AND THEIR USE

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application serial no. 11/497,152 filed July 31, 2006, which is a continuation-in-part application of U.S. application Ser. No. 10/155,305, filed May 24, 2002, which, in turn, is a continuation-in-part application of PCT/US00/31933 published in English on May 31, 2001 as WO/2001/037788. The entire contents of each of those applications is incorporated herein as if set forth fully again.

BACKGROUND OF THE INVENTIONS

[0002] With an aging population, there has been an increase in the study of aging as it relates to the human body and, more particularly, human skin. For example, the treatment of aging skin exhibited by the presence of fine lines, wrinkles, and the like has received a great deal of attention. The dermal signs of aging such as fine lines, wrinkles, laxity, and hyperpigmentation have been fought through many tactics including surgery, laser treatment and cosmetics. Cosmetic treatments include the use of various creams and lotions to alter the effects of dermal aging. Much of the literature in the prior art focuses on the use of a single primary component to prevent one of several deleterious aging affects. For example, one tactic has been to use one or more hydroxy acids or retinoic acid to stimulate the re-growth of dermal cells, without other components. This approach is flawed because it does not recognize that aging is caused by the deleterious interaction of multiple agents on the skin, from multiple sources, causing damage to the skin through multiple simultaneous damage pathways.

[0003] More comprehensive studies have found that environmental factors, such as stress, sun exposure, and impurities in food, water, and air, also adversely

effect components of the epidermal and dermal layers of the skin which, in turn, impact and alter the appearance of the skin and lead to an appearance of premature aging. For example, factors such as free radicals, reactive nitrogen species ("RNS"), reactive oxygen species ("ROS"), and other oxidizing species ("OOS") that may or may not possess characteristics of each free radicals, RNS, and ROS, can adversely impact the human body including the skin. Particular factors within the groups noted above that have been found to impact and adversely affect the appearance of the skin include nitric oxide, superoxide radicals, hydrogen peroxide, and hydroxide free radicals. These factors have been variously implicated in a number of skin conditions including photodamage, general aging of the skin, contact dermatitis, wrinkling, lipid peroxidation, enzyme degradation, reduction and breakdown of collagen and/or elastin, degradation and inhibited reproduction of DNA, inflammation, and general damage to the skin tissue.

[0004] The ROS species include superoxide (O2--), hydrogen peroxide (H2O2), peroxy radicals (HO2 and RO2) alkyl peroxide (R2O2), hydroxyl radical (OH), alkoxy radical (OR), and singlet oxygen. The OOS species include hypohalous acids (HOX) (where X is chloride, bromide, iodide), Z-amines (where Z is either chlorinated or ammoniated amine containing compounds, the reactive nitrogen species ("RNS") nitric oxide (NO), ammonia, cyclooxygenase, phospholipase A2, phospholipase C and transition metals.

[0005] Each of the ROS directly or acting as an intermediate are thought to act on cell membrane and/or other cellular components including organelles and their contents to adversely impact the skin. Thus, there is a need for a topical skin treatment composition and method that provides a defense against each of the ROS, RNS, and

OOS noted above. In addition, it would be desirable if such a composition repaired damage caused by the ROS, RNS, and OOS noted above.

SUMMARY OF THE INVENTIONS

[0006] The present inventions are directed to compositions that include selected components that provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species noted above that adversely effect the human body, including the skin. The inventions, therefore, also include methods for applying the compositions of the invention to the skin, to inhibit the causative factors that adversely effect the skin, and thereby treat and improve the quality of the skin. Generally, the compositions and methods of this invention are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species noted above, on the human body, including the skin. Thus, the present invention includes various compositions that include at least one anti-free radical component and/or an anti-superoxide component and/or an anti-hydrogen peroxide component and/or an anti-hydroxyl radical component and/or a chain breaking component.

[0007] Embodiments of the present invention include compositions that include a component that aids in cellular energy product and/or a component that aids in collagen synthesis and/or elastin synthesis and/or inhibits their degradation, and/or a component that aids in or provides cellular activity. For example, a composition of the present invention that has been found to positively effect one or more of the foregoing

factors, includes a citrus component, such as a grapefruit component, such as grapefruit extract, a superoxide dismutase component, a glutathione component, a tetrahydrodiferuloylmethane component and/or a turmeric component, such as a tumeric extract, a bioflavonoid component, such as a citrus bioflavonoid component, a grape component, such as grape seed extract, a green tea component, such as a green tea extract, tocopherol, and/or a tocopheryl derivative such as tocopheryl acetate.

[0008] Another embodiment of the present invention that has similarly been found to positively effect factors that improve the health of skin, is a composition that includes a soybean component, such as a soybean protein component, a rice component, such as rice protein and more particularly hydrolyzed rice protein, and a sunflower seed component, such as a sunflower seed extract.

[0009] A further composition of the present invention includes a centella asiatica component, such as a centella asiatica extract, a corn kernel component, such as a corn kernel extract, a seaweed component, such as a seaweed extract, and ubiquinone (coenzyme Q).

[0010] Another composition of the present invention includes a rosemary component, such as a rosemary extract, a lecithin component, a ceramide component, such as a ceramide 3 component, a sitosterol component, such as beta sitosterol, a glycerin component, a panthenol component, a proline component, such as L- proline, and a hyaluronate component, such as sodium hyaluronate.

[0011] As explained further below, the present invention further includes compositions containing a combination of one or more of each of the foregoing

composition components mentioned in the paragraphs above and, more particularly, the active agents contained therein.

[0012] Accordingly, methods of applying the compositions to the skin, to maintain and/or improve the condition of the skin of an individual for any of the reasons noted above, are also provided. Thus, the compositions may be applied to the skin for example, by topically applying an amount, such as an effective amount, of one or more of the various compositions according to the invention.

[0013] Processes for preparing the compositions according to the present invention are provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] FIG. 1 is a graph showing the increase in erythema 30 minutes after UV exposure on human skin to which formulations were applied.

[0015] FIG. 2 is a graph showing the increase in erythema 10 hours after UV exposure on human skin to which formulations were applied.

[0016] FIG. 3 is a graph showing the effect of samples on procollagen secretion. The data are expressed as the collagen/viability ratio calculated by dividing the amount of procollagen detected in the tissue culture supernatants by WST-1 reduction as an indicator of cellular viability following the exposure period.

[0017] FIG. 4 is a graph showing the effect of samples on elastin secretion. The data are expressed as the elastin/viability ratio calculated by dividing the amount of elastin detected in the tissue culture supernatants by WST-1 reduction as an indicator of cellular viability following the exposure period.

[0018] FIG. 5 is a graph showing the effect of samples on MMP-1 activity. The data are expressed as % control MMP-1 activity. The horizontal line denotes 100% activity.

[0019] FIG. 6 is a graph showing the effect of samples on MMP-9 activity. The data are expressed as % control MMP-9 activity. The horizontal line denotes 100% activity.

[0020] FIG. 7 is a graph showing the effect of samples on Elastase activity. The data are expressed as % control elastase activity. The horizontal line denotes 100% activity.

[0021] FIG. 8 is a graph showing the effect of samples on NO production by RAW 264.7 cells. Data are expressed as % NO produced compared to the LPS stimulated positive control. L6 = Lipochroman-6, NT = Nutriene tocotrienols, TQS = γ-Tocopherylquinone S, VC = Viapure Citrus, SZ = Soybean Zymbiosome, and NPR = NAB Pikea robusta.

[0022] FIG. 9 is a graph showing the effect of samples on lipid staining in HEK001 keratinocytes. Data are expressed as % control lipid from untreated cells.

DETAILED DESCRIPTION OF THE INVENTIONS

[0023] As explained in the summary above, the present invention provides compositions that provide a defense mechanism against a variety of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. These compositions assist in the maintaining and/or improving of the condition of the skin by, for example, increasing energy in cells of the

skin and/or inhibiting adverse enzymes and/or maintaining and/or improving the quality and quantity of elastin, collagen, and glycosaminoglycan in the skin.

[0024] Compositions of the present invention will, generally speaking, include one or more of:

a citrus component, such as a grapefruit component, such as a grapefruit extract component, preferably a grapefruit peel extract, and preferably the component of apigenin;

a superoxide dismutase component;

a glutathione component;

a tetrahydrodiferuloylmethane component;

a phenolic component, such as a polyphenol component;

an essential oil component;

an ascorbic acid component;

a turmeric component, such as a tumeric extract;

a flavonoid component, such as a bioflavonoid component, such as a citrus bioflavonoid;

a grape component, such as grape seed extract;

a green tea component, such as a green tea extract;

tocopherol and/or derivatives thereof, such as tocopheryl acetate;

a soybean component, such as a soybean protein component;

a rice component, such as rice protein, and more particularly hydrolyzed rice protein;

a sunflower seed component, such as sunflower seed extract;

an octinoxate component,

a butyl methoxydibenzoyl-methane component;

a centella asiatica component, such as centella asiatica extract;

a corn kernel component, such as a corn kernel extract;

a seaweed component, such as a seaweed extract preferably laminaria digitata extract;

an ascorbyl tetraisopalmitate component;

a coenzyme component, such as ubiquinone (coenzyme Q);

a rosemary component, such as a rosemary extract, and preferably the component of ursolic acid;

a lecithin component;

a ceramide component, such as ceramide 3;

a beta sitosterol component;

a glycerin component;

a panthenol component, such as d-panthenol;

an adenosine component;

a proline component, such as L- proline;

a hyaluronate component, such as sodium hyaluronate;

a carbohydrate component;

a B vitamin component; and

a phylate component.

[0025] As used herein, the term "complex" means an admixture of various ingredients selected to focus around a common theme relating to the health and maintenance of mammalian skin. One such complex of ingredients could be focused on mediating effects of reactive oxygen and nitrogen species.

[0026] One particular embodiment of such a composition that is generally useful for its antioxidant property of preventing free radical damage to the skin, thereby protecting against the aging effects from free radical damage, includes the combination of a citrus component, and preferably a citrus component that contains apigenin. The citrus component may be derived from lemon, orange, tangerine, grapefruit, peppers, buckwheat, black currents, apricots, cherries, grapes and prunes. A preferred citrus component is a grapefruit component, and more particularly, a grapefruit extract that includes apigenin or simply is apigenin. It has been found that citrus components, and in particular citrus components that contain apigenin, such as a fruit extract and, more particularly, a grape fruit extract, inhibit damage caused by the reactive nitrogen species, in particular, nitric oxide (NO) production. The citrus component has been further found to inhibit lipid peroxidation, as well as inflammation caused by free radicals. Thus, compositions of the present invention that contain a citrus component, and in particular a grape fruit extract component, preferably containing apigenin, have been found to inhibit damage to the skin caused by nitric oxide production and/or lipid peroxidation and/or inflammatory factors such as inflammation caused by free radicals.

[0027] The composition generally further includes a superoxide dismutase component, which inhibits damage to proteins, elastin, collagen, and DNA, caused by superoxides that attack for example, enzymes; and a glutathione component, which inhibits damage caused by hydrogen peroxide. Additional components of this composition may include a phenolic component and/or one or more of the so-called "essential oils" and/or ascorbic acid ("vitamin C") and/or tetrahydrodiferuloylmethane, which may, for example, be found in a tumeric component, such as a tumeric extract.

Further components may include a flavonoid component, such as a bioflavonoid component, such as a citrus bioflavonoid component from, for example, grapefruit, lemon, or orange; and a polyphenol component which may, for example, be found in a grape component, such as grape seed extract, and preferably procyanidolic oligomers, a green tea component, preferably including polyphenols, and particularly epigallocatechin gallate (EGCG), tocopherol, and/or tocopheryl acetate, are each components that inhibit damage caused by hydroxyl radicals which attack lipids.

[0028] Thus, in one particular embodiment, this composition includes grapefruit extract in an amount of from about 0.01% to about 1%, superoxide dismutase in an amount of from about 0.0001% to about 0.01%, glutathione in an amount of from about 0.01% to about 1%, tetrahydrodiferuloy methane or a tumeric extract in an amount of from about 0.001% to about 1%, citrus bioflavonoids in an amount of from about 0.001% to about 1%, grape seed extract in an amount of from about 0.001% to about 1%, green tea extract in an amount of from about 0.01% to about 1%, tocopherol in an amount of from about 0.01% to about 2%, tocopheryl acetate in an amount of from about 0.01% to about 5%.

[0029] Thus, as will be appreciated, a composition generally as described above, may maintain and/or improve skin quality, thereby maintaining a youthful appearance, by reducing the detrimental effects of one or more of inflammation, lipid peroxidation, and degradation of collagen, elastin, and DNA.

[0030] In another particular embodiment of the present invention, a composition will generally include a soybean component, such as a soybean protein component, and preferably the isoflavones, such as genistein and daidzein. The

soybean component has been found to be an inhibitor of the enzyme elastase, which is released to the skin in response to such factors as exposure the UV rays, dryness, and environmental stresses generally. Thus, the soybean component helps maintain and/or increase firmness and elasticity of the skin, particularly those that derive from the UV rays of sun exposure. This embodiment of the composition will generally also include a rice component, such as rice protein, and more particularly a hydrolyzed rice protein, which has an inhibitory effect on the enzyme collagenase. The inhibition of collagenase aids in protecting collagen in the skin, thereby maintaining and/or improving the condition of the skin with respect to elasticity, firmness, wrinkling, dryness, and age spots. A sunflower seed component, such as sunflower seed extract, may also be included in this embodiment. The sunflower seed component has been found to act as an anti-glycation factor, and to maintain and/or improve the condition of the skin by delaying the changes that cause collagen to become rigid with age and other detrimental factors discussed above. The composition may further include an octinoxate component and/or a butyl methoxydibenzyoylmethane component.

[0031] Thus, in one particular embodiment, this composition includes soybean protein (Glycine Soja) in an amount of from about 0.01% to about 3%, hydrolyzed rice protein in an amount of from about 0.01% to about 3%, sunflower seed extract in an amount of from about 0.01% to about 3%.

[0032] A further particular embodiment of the present invention, is a composition that includes a centella asiatica component, such as centella asiatica extract. The centella asiatica component has been found to promote collagen and elastin synthesis, thereby maintaining or improving the firmness, elasticity, and general

strength of the skin. The primary active constituents are saponins (triterpenoids), that include asiaticoside, madecassoside, and madasiatic acid. A corn kernel component, such as a corn kernel extract, and more particularly myo-inositol, may be included in this embodiment, and it provides several benefits that include assistance in production and storage of energy in the cell, inhibition of lipid peroxidation, and it is generally a powerful antioxidant. Components of corn kernel extract that may separately or in combination be included in a composition, include nitrogenous elements, carbohydrates, B vitamins, trace elements, and/or myo-inositol in the form of phylate. A seaweed component, such as a seaweed extract (e.g., laminaria digitata extract), may be further included in this embodiment and, when included, it assists in increasing intercellular ATP rate and increasing oxygenation of cells and tissues, thereby generally increasing the structure of skin. Finally, a ubiquinone (coenzyme Q) component may be included and it acts as a coenzyme for various important enzymatic pathways particularly in the production of energy in cells, and optionally with ascorbyl tetraisopalmitate.

[0033] Thus, in one particular embodiment, this composition includes Centella Asiatica extract in an amount of from about 0.01% to about 3%, corn kernel extract in an amount of from about 0.01% to about 3%, seaweed extract in an amount of from about 0.01% to about 3%, coenzyme Q-10 in an amount of from about 0.001% to about 1%.

[0034] A further particular embodiment of the present invention is a composition that generally provides a hydrolipid matrix to the skin. This composition will generally include a rosemary component, such as a rosemary extract, and preferably rosmarinic acid, phenolic diterpenes, carnosol, carnosic acid, and/or ursolic acid, or

simply is ursolic acid. The rosemary extract will preferably be an extract obtained form the leaf of a rosemary. The rosemary component will preferably be encapsulated in a liposome to enhance delivery. Additional components will generally include one or more of a lecithin component, a ceramide 3 component, a phospholipid such as a beta sitosterol component, a glycerin component, a panthenol component, a proline component, such as L-proline, and a hyaluronate component, such as sodium hyaluronate. Subcombinations of components of the above composition will preferably include a rosemary component, such as a rosemary extract, and preferably an extract of rosemary leaf, and a lecithin component. This subcombination aids in lipid retention and in forming a moisture layer barrier in and on the skin. A further subcombination of the above composition preferably includes a lecithin component, a ceramide 3 component, and a beta sitosterol component, or preferably includes a ceramide 3 component and a beta sitosterol component. This subcombination of the above components also aids in lipid retention and in forming a moisture layer barrier in and on the skin.

[0035] Thus, in one particular embodiment, this composition includes rosemary extract in an amount of from about 0.0001% to about 1%, a lipid complex that includes ceramide 3 in an amount of from about 0.001% to about 0.1% and a beta-sistosterol in an amount of from about 0.0001% to about 0.1%, glycerin in an amount of from about 0.1% to about 10%, panthenol in an amount of from about 0.01% to about 1%, proline in an amount of from about 0.001% to about 1%, and sodium hyaluronate in an amount of from about 0.001% to about 5%.

[0036] As will be appreciated, each of the foregoing compositions and subcombinations may be used alone, or may be used in combination with additional components to form a further new formulation. The present invention thus further includes compositions containing a combination of one or more of each of the foregoing composition components in further combination with additional components discussed below.

[0037] The compositions of the present invention may also include a cosmetically or pharmaceutically acceptable carrier. Components of the compositions may be encapsulated, such as in liposomal capsules. When a carrier is present, the complex forms from about 0.01% to about 10% by weight of the total composition, preferably from about 1% to about 7% by weight of the total composition.

[0038] In general, the anti-superoxide component may include those materials having anti-superoxide activity and, in particular, those having superoxide dismutase activity. In other words, it includes those components that can catalyze a dismutation reaction. For example, it includes superoxide dismutase (SOD), SODs modified by grafting polyalkylene oxide, polyethylene glycol, polysaccharide or acylated groups, salts of SOD, substances containing such SOD products, porphorins and materials with superoxide dismutase-like activity. In this respect, it includes those products mentioned in EP 223 257, the relevant contents of which are incorporated herein by reference.

[0039] All the superoxide dismustases described above, as well as the variants and equivalents that a person of skill in the art can deduce from the literature may be suitable as SODs for use in the present invention. In addition, they can be of differing origins. For example, they may be animal (bovine, porcine, and the like),

human (blood), or plant (fungi, algae, spinach, and the like). They may also be obtained from bacteria or yeast, or alternatively by a biotechnological route. Examples of SODs that may have application in the present invention are described in U.S. Pat. No. 5,526,507, the contents of which is incorporated herein by reference. The SOD may form from about 0.0001% to about 5%, 0.01% to about 5% by weight of the complex. More, preferably, the SOD may be included in the complex in an amount from about 0.1% to about 2% by weight.

[0040] In general, the anti-hydrogen peroxide component may be a thiol or thiol derivative. In the context of the present invention, the term thiol is to be understood to be an organic compound characterized by the --SH group. Thiol derivatives are organic compounds that are either derivatives that retain the --SH group or are thio ethers or thio esters, in which case the --SH group is converted into the --SR group.

[0041] Compounds that are to be understood as being identical to the thiols or thiol derivatives according to the invention are those that are formed by tautomerism, di- or oligomerization by hydrogen bonding, hydration or other spontaneous rearrangement from the thiols or thiol derivatives. If a derivative is in equilibrium with an isomer by a different type of rearrangement, for example, migration of an alkyl group, this isomer is regarded as being included in the thiols and thiol derivatives of the invention.

[0042] Suitable thiol and thiol derivatives may include captopril, cysteamine, ergothioneine, mercaptopropionylglycine, penicillamine, N-acetylcysteine, S-acetylcysteine, N,S-diacetylcysteine, N,S-diacetylcysteinamide, cysteine ethyl ester, N-acetylcrysteine ethyl ester, S-acetylcysteine ethyl ester, N,S-diacetylcysteine ethyl

ester, thioglycolic acid, cysteine, homocysteine, glutathione, thioglycerol, thiomalic acid, 2-mercaptopropionic acid, 3-mercaptopropionic acid, thiodiglycol, 2-mercaptoethanol, dithioreitol, thioxanthene, thiosalicylic acid, thiolactic acid, thiopropionic acid, thiodiglycolic acid, lipoic acid, and cosmetically acceptable salts thereof.

[0043] As used herein, the cosmetically acceptable salts include, but are not limited to alkali metal salts, e.g., sodium, lithium, potassium, and rubidium salts; alkaline earth metal salts, e.g., magnesium, calcium, and strontium salts; non-toxic heavy metal salts, e.g., aluminum and zinc salts; boron salts; silicon salts; ammonium salts; trialkylammonium salts, e.g., trimethylammonium and triethylammonium, and tetraalkylonium salts.

[0044] Generally, the anti-hydrogen peroxide component may be incorporated into the complex in an amount from about 0.001% to about 5% by weight, preferably from about 0.01% to about 2.5%, more preferably from about 0.1% to about 1% by weight of the complex.

[0045] Generally, anti-hydroxyl radical components can include one or more of the following: tocopherol, tocopherol derivatives, tetrahydrodiferuloylmethane, grape seed extract (e.g., vitis vinifera (grape) seed extract), grape fruit extract (e.g., citrus grandis (grapefruit) fruit extract), green tea extract (e.g., camellia sinensis (leaf) extract), turmeric acid, curcuminoids, tetrahydrocurcuminoids catechins, epigallocatechin 3-0-gallate and polyphenols, oligomeric proanthocyanidins, bioflavonoids, flavonoids, and mixtures thereof.

[0046] Tocopherol (Vitamin E) and its derivatives such as esters of tocopherol are useful in the composition of the present invention. Suitable tocopherols include the

monomethyl, dimethyl, or triethyl derivatives of tocol, including but not limited to, alpha tocopherol, beta tocopherol, gamma tocopherol, delta tocopherol, epsilon tocopherol, zeta tocopherol, and eta tocopherol. Suitable esters of tocopherol include but are not limited to tocopheryl acetate, tocopheryl succinate, tocopheryl benzoate, tocopheryl propionate, tocopheryl sorbate, tocopheryl oleate, tocopheryl orotate, tocopheryl linoleate, tocopheryl nicotinate, and the 2-ethyl-hexanoate ester.

[0047] When the tocopherol and/or its derivatives are included in the complex of the present invention, they are used at level from about 0.01% to about 98%, preferably from about 0.01% to about 5%, and from 0.01% to about 2%.

[0048] Tetrahydrodiferuloylmethane and/or turmeric extract may also be incorporated into the complex at levels from about 0.1% to about 20% by weight of the complex, preferably from about 1% to about 10% by weight.

[0049] As discussed above, grape seed extract and complexes of grape seed extract with phospholipids may also be beneficial for use in the present invention. The extracts from grape seed include a mixture polyphenols such as epicatechin, proanthocyanidins, and catechins. A suitable complex of grape seed extract and phospholipid is described in U.S. Pat. No. 4,963,527, the contents of which are incorporated herein by reference.

[0050] When incorporated into the complex, the grape seed extract or its complex with phospholipids is present in an amount from about 0.001% to about 5% by weight of the complex, preferably from about 0.01% to about 2.5% by weight. Green tea extract may be included in the same amounts as the grape seed extract.

[0051] Flavonoids and bioflavonoids may also be useful in the present invention. It has been reported in Bravo, Polyphenols: Chemistry, Dietary Sources, Metabolism, and Nutritional Significance, Nutrition Reviews, Vol. 56, No. 11, 317-33 (November, 1998), the contents of which are incorporated herein by reference, that flavonoids may be subdivided into 13 classes shown below:

Chalcones



Dihydrochalcones



Aurones





Flavones



Flavonols



Dihydroflavonol



Flavanones



Flavanol



Flavandiol or:
leucoanthocyanidin



Anthocyanidin



Isoflavonoids





Biflavonoids



Proanthocyanidins or condensed tannins



[0052] Flavonoids have, in general, the common structure of diphenylpropanes (C6-C3-C6) and consist of two aromatic rings linked through three carbons that usually form an oxygenated heterocycle. The basic structure is shown below:



[0053] Flavonoids occasionally occur in plants as aglycones, although they are most commonly found as glycoside derivatives.

[0054] Specific suitable flavonoids for use in the present invention include but are not limited to rutin, citrin, quercitin, hesperidin, naringen, taxifolin, catechin,

epicatechin, eriodictyol, naringenin, troxerutin, chrysin, tangeretin, luteolin, epigallocatechin, epigallocatechin gallate, fisetin, kaempferol, galangin, gallocetechin, epicatechin gallate, apigenin, diosmetin, myricetin, genistein, daidzein, or derivatives thereof. The flavonoids may be derived from any suitable source. A preferred source is from citrus.

[0055] When flavonoids are incorporated into the complex, they are present at a level from about 0.001% to about 20% by weight of the complex, preferably from about 0.01% to about 10% by weight.

[0056] Other specialty components may also be included such as palmitoyl hydroxypropyltrimonium amylopectin. In one embodiment, the palmitoyl hydroxypropyltrimonium amylopectin can be mixed with camellia sinensis extract. This may be present in amounts ranging from about 0.001% to about 2% by weight of the complex.

[0057] The chain breaker may include the same components as those described above for the anti-hydroxyl radical component. Thus, one or more of the above anti-hydroxyl radical components may also serve as a chain breaker component. Chain breaking antioxidants are those components that can break the chain reaction once lipid peroxidation is initiated.

[0058] As noted above, the complex composition may also include components selected to repair the damage caused by the ROS. In one embodiment, the compositions of the present invention includes at least one component that provides cellular energy production, at least one component that aids collagen synthesis, and/or

at least one component that aids or provides cellular activity. These components may be used singly or, desirably, in combination.

[0059] A desirable cellular energy production component includes the ubiquinones. Ubiquinones are widely found in bacteria, fungi, yeasts, plants, and animals. It is known that different species produce isoforms (Q-n) with different numbers of isoprene units (n). For example, the number of isoprene units is 6 (Q6) in some microorganisms, nine (Q9) in plants, and ten (Q10) in humans. Coenzyme Q10 or 2,3,-dimethoxy-5-methyl-- 6-decaprenyl-benzoquinone functions to recover and maintain respiration and promotes ATP production in terms of energy supply for cellular activities. Derivatives of the ubiquinones such as ubiquinols may also be useful

[0060] The cellular energy production component, for example, coenzyme Q10, is incorporated into the complex in an amount ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.

[0061] To repair damage caused by ROS, it is desirable to include a component that will promote collagen synthesis. It has been suggested that hydroxy acids including alpha and beta hydoxy acids may be useful in this regard. As a result, the present invention contemplates including one or more alpha or beta hydroxy acids. Suitable examples include lactic, malic, glycolic, citric, and salicylic acid.

[0062] In addition, it has been found that ascorbic acid (Vitamin C) and its derivatives promote collagen synthesis. The ascorbic acid derivative useful in the present invention includes all enantiomers whether singly or in combination. Preferably, the ascorbic acid is provided in the levo form. In addition, the ascorbic acid or its derivatives may be in a water soluble or an oil soluble form.

[0063] Non-exclusive examples of the vitamin C (ascorbic acid) derivatives are, for instance, the alkyl esters of L-ascorbic acid where the alkyl portion has from 8 to 20 carbon atoms. With respect to the esters, they may be selected from the group consisting of fatty acid mono-, di-, tri- or tetra-esters of ascorbic acid. For example, such esters include, but are not limited to ascorbyl palmitate, ascorbyl laureate, ascorbyl myristate, ascorbyl stearate, ascorbyl dipalmitate, ascorbyl dilaurate, ascorbyl dimyristate, ascorbyl distearate, ascorbyl tripalmitate, ascorbyl trilaurate, ascorbyl trimyristate, ascorbyl tristearate, ascorbyl tetrapalmitate (tetrahexyldecyl ascorbate), ascorbyl tetralaurate, ascorbyl tetramyristate, ascorbyl tetrastearateL-ascorbyl palmitate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, L-ascorbyl isostearate, L-ascorbyl distearate, L-ascorbyl diisostearate, L-ascorbyl myristate, L-ascorbyl isomyristate, L-ascorbyl 2-ethylhexanoate, L-ascorbyl di-2-ethylhexanoate, L-ascorbyl oleate and L-ascorbyl dioleate, tetrahexyl decyl ascorbate; phosphates of L-ascorbic acid such as L-ascorbyl-2-phosphate and L-ascorbyl-3-phosphate; sulfates of L-ascorbic acid such as L-ascorbyl-2-sulfate and L-acorbyl-3-sulfate; their salts with alkaline earth metals such as calcium and magnesium.

[0064] With respect to the salts, they may be selected from the phosphates and sulfates, preferably phosphate. The ascorbic acid phosphate is generally selected from L-ascorbic acid 3-phosphate, L-ascorbic acid 2-phosphate, L-ascorbic acid 3-pyrophosphate and bis (L-ascorbic acid 3,3-) phosphate. Preferably, the ascorbic acid phosphate is magnesium or sodium ascorbyl phosphate; more preferably, magnesium ascorbyl phosphate. Likewise, the ascorbic acid sulfate is generally selected from L-

ascorbic acid 3-sulfate, L-ascorbic acid 2-sulfate, L-ascorbic acid 3-pyrosulfate and bis (L-ascorbic acid 3,3-) sulfate.

[0065] The collagen synthesis component, for example, the ascorbic acid and its derivatives, is incorporated in the complex in an amount ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.

[0066] It is believed that retinoids may affect cellular activity and thus it is desirable to incorporate retinoids in the complex of the present invention. The retinoids include retinol, retinal (Vitamin A aldehyde), and retinyl esters such as retinyl acetate, retinyl butyrate, retinyl propionate, retinyl octanoate, retinyl laurate, retinyl palmitate, retinyl oleate, and retinyl linoleate.

[0067] Retinoids tend to irritate the skin and therefore, it is desirable to incorporate them in the complex at levels so as to minimize the potential irritation. Alternatively, irritancy mitigants may be incorporated into the compositions to assist in preventing undue discomfort to the user while potentially permitting the dosage level of retinoid to be increased. Such irritancy mitigants include, but are not limited to ceramides, pseudoceramides, fatty acids, cholesterol, phospholipids, panthenol, oat extract, allantoin, ginkgo biloba, licorice extract, calendula, ginseng, butchers broom, and the like.

[0068] The cellular activity component, for example, the retinoid, is incorporated in the complex at a level ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.

[0069] The complex compositions according to the present invention are generally mixed with a pharmaceutically or cosmetically acceptable vehicle or carrier.

The complex compositions of the present invention may be formulated as a solution, gel, lotion, cream, ointment, oil-in-water emulsion, water-in-oil emulsion, or other pharmaceutically or cosmetically acceptable form. The complex compositions of the present invention may also contain various known and conventional cosmetic components so long as they do not detrimentally affect the desired effects.

[0070] The pharmaceutically acceptable or cosmetically acceptable vehicle acts as a dilutant, dispersant, or carrier for other materials present in the complex composition, so as to facilitate their distribution when the complex composition is applied to the skin.

[0071] Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners, and powders. For example, the following vehicles can be used alone or as a combination of one or more vehicles.

[0072] Vehicles may also include propellants such as propane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide; and solvents such as ethyl alcohol, isopropanol, acetone, ethylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, or powders such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica, sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.

[0073] Emollients, such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl

alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil, sunflower seed oil, avocado oil, sesame seed oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum jelly, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate.

[0074] As used herein, "emollients" refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin. A wide variety of suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of suitable materials.

[0075] The composition can optionally comprise sunscreens such as inorganic and organic sunscreens to provide protection from the harmful effects of excessive exposure to sunlight during use of the complex composition of the present invention. Examples of suitable sunscreens include those described in the U.S. OTC Sunscreen Monograph, such as octinoxate, and butyl methoxy dibenzoylmethane, the contents of which is incorporated herein by reference.

[0076] The composition of the invention can accordingly comprise from 0.1 to 10%, preferably from 1 to 5% by weight of an organic sunscreen material.

[0077] The composition optionally can also comprise as a sunscreen titanium dioxide or zinc oxide having an average particle size of from 1 to 300 nm, iron oxide

having an average particle size of from 1 to 300 nm, silica, such as fumed silica having an average particle size of from 1 to 100 nm. It should be noted that silica, when used as an component in the emulsion according to the invention can provide protection from infrared radiation.

[0078] Ultrafine titanium dioxide in either of two forms, namely water-dispersible titanium dioxide and oil-dispersible titanium dioxide may be used. Water-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which are uncoated or which are coated with a material to impart a hydrophilic surface property to the particles. Examples of such materials include aluminum oxide and aluminum silicate. Oil-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which exhibit a hydrophobic surface property, and which, for this purpose, can be coated with metal soaps such as aluminum stearate, aluminum laurate, or zinc stearate, or with organosilicone compounds.

[0079] By "ultrafine titanium dioxide" is meant particles of titanium dioxide having an average particle size of less than 100 nm, preferably from 10 to 40 nm and most preferably from 15 to 25 nm. The total amount of titanium dioxide that can optionally be incorporated in the composition according to the invention is from 1 to 25%, preferably from 2 to 10% and ideally from 3 to 7% by weight of the composition.

[0080] A particularly convenient form of the composition is an emulsion, in which case an oil or oily material (emollient) will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion.

[0081] The composition can also comprise water, usually up to 95%, preferably from 5 to 95% by weight.

[0082] The composition can also optionally comprise a high molecular weight silicone surfactant that can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.

[0083] The silicone surfactant may be a high molecular weight polymer of dimethyl polysiloxane with polyoxethylene and/or polyoxpropylene side chains having a molecular weight of from 10,000 to 50,000. When used, the dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane. Ideally, the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.

[0084] Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer).

[0085] A preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.

[0086] The amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.

[0087] Examples of conventional adjuncts which can optionally be employed include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy tofuene; humectants, such as glycerol, ethoxylated glycerins such as glycereth-26, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax; plant extracts, such

as Aloe Vera, cornflower, witch hazel, elderflower, cucumber; as well as acerola cherry fermentate, thickeners; activity enhancers; colorants; and a fragrance, such as perfumes, may be included in a composition prepared in accordance with the present invention. Cosmetic adjuncts can form the balance of the composition.

[0088] It may also be desirable to incorporate anti-inflammatory and/or anti-irritant agents. The natural anti-inflammatory and/or anti-irritant agents are preferred. For example, licorice and its extracts, dipotassium glycyrrhizinate, oat and oat extracts, candelilla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia cordifolial), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), may be used.

[0089] Skin conditioning agents that may be included, as mentioned above, are hyaluronic acid, its derivatives and salts including sodium hyaluronate, plant extracts such as kola nut, guarana mate, algae extract, proline, L-proline, and skin benefit agents such as ceramides, glycoceramides, pseudoceramides, sphingolipids such as sphingomyelins, cerebrosides, sulphatides, and ganglioside, sphingosines, dihydrosphingosine, phytosphingosines, phospholipids, either separately or in mixtures. Fatty acids may also be combined with these skin benefit agents. For example, the ceramides and glycoceramides include those described in U.S. Pat. Nos. 5,589,178, 5,661,118, and 5,688,752, the relevant portions of which are incorporated herein by reference. For example, the pseudoceramides include those described in U.S. Pat. Nos. 5,198,210, 5,206,020, and 5,415,855, the relevant disclosures of which are incorporated herein by reference.

[0090] Generally, compositions according to the present invention may be prepared in accordance with conventional procedures that are known in the art. For example, components of the present invention may be combined by sequential addition, with or without preference to order, followed by mixing to form a mixture. For example, components that are water soluble will generally be combined to forma water phase, and components that are fat soluble will generally be combined to form a fat phase. Thereafter, the two phases may be emulsified and then combined with carriers, etc. Alternatively, compositions may be prepared by admixing, such as in a one-pot system.

[0091] As noted above, the compositions of the present invention may be administered to an individual, preferably by topical application to the skin of the individual. The compositions may be applied in an amount effective to inhibit free radicals, reactive oxygen species, and other oxidizing species. Obviously, an individual may apply as much or as little of the composition as they desire or believe necessary but, for example, a composition of the present invention may be applied to the skin in an amount of about 1 mg/cm^2 to about 3 mg/cm^2 of skin. Preferably, the compositions of the present invention will be applied in an amount of about 2 mg/cm^2 per square inch of skin. Generally, the composition should be applied twice a day, such as in the morning and in the evening.

[0092] The compositions preferably include components for enhancing the transportation of the active components into the epidermal and dermal layers of the skin. Such components include dimethyl sulfoxide (DMSO) or n-decylmethyl sulfoxide (NDMS).

EXAMPLES

[0093] The following examples are intended to illustrate, but not limit, the present invention. The examples below illustrate the effects of components of the ocmpositions of the present invention. They also set forth compositions according the present invention in combination with additional optional components that may alternatively be incorporated into any of the compositions set forth above.

EXAMPLE 1

Studies were performed to explore the effect of samples on collagen and elastin synthesis. Two assay systems were utilized for these studies. Human dermal fibroblasts, as these cells actively synthesize procollagen, and elastin.

Samples were diluted in media. RON SBD 101, Centella asiatica, and vitamin C were prepared at 0.001, 0.01, and 0.1% concentrations. The remaining samples were prepared at 0.1, 1, and 10% concentrations. Centella asiatica was prepared as an extract in DMSO:ethanol:water at 50:30:20. Human dermal fibroblasts (Hs-27) were plated in 24 well plates and were incubated overnight. The following day, the cells were treated with the samples at the concentrations previously indicated. Supernatant fluids were collected and tested for the presence of procollagen using a commercially available ELISA kit and elastin using the Fastin Elastin kit.

The levels of collagen produced by the cells are shown in figure 3. Collagen synthesis is expressed as a ratio of the amount of procollagen detected divided by viability to allow for any toxic effects of the samples. The data demonstrate that the Centella asiatica sample was most potent at inducing new collagen synthesis at a concentration of 0.1%. The Biopeptide CL and Biopeptide EL samples also induced a

detectable increase in collagen synthesis at a concentration of 10%. The other samples had no detectable effect on procollagen synthesis.

The data in figure 4 show the effect of the samples on elastin secretion. The data are again expressed as the ratio of the amount of elastin secreted divided by the viability of the cells at the time of supernatant collection. Like it did for collagen secretion, the Centella asiatica sample was the most potent inducer of elastin. Biopeptide CL and Biopeptide EL also induced detectable increases in elastin secretion. Finally, the Odraline and Biodynes EMPP samples induced slight increases in elastin at the highest concentration used (10%).

The results show that Centella asiatica is a potent inducer of both collagen and elastin. Additionally, the results suggest that the Biopeptide CL & EL samples induced both collagen and elastin although a high concentration of these materials is needed in order to induced the observed biological effect.

EXAMPLE 2

Sixteen samples were tested for their effects on three different enzymes (matrix metalloproteinases or MMPs) which are involved with breakdown of extracellular matrix proteins. Elhibin was the only sample that inhibited MMP-1. The most potent activators of MMP-1 were CoQ10, BVOSC Ascorbyl ester, Sophorine, Lemon bioflavonoids, ACTIMP 1.3.9, Lemon and mixed citrus extracts, and Kelpadelpie. Most of the samples had no effect of MMP-9, with only BVOSC ascorbyl ester being a strong inhibitor. The strongest inhibitors of elastase were Collalift, Alphinia leaf, Elhibin, Sophorine, Lemon bioflavonoids, ACTIMP 1.3.9, Lemon and mixed citrus extracts,

Kelpadelpie, Extracellium, and Colhibin. Therefore, base on the desired profile of MMP-1 and elastase inhibition while having no effect of MMP-9, elhibin would be the raw material of choice.

The matrix metalloproteinases (MMP) are a group of zinc dependent enzymes, which degrade varying components of the extracellular matrix in both normal and diseased tissue. MMP-1 (interstitial collagenase) is thought to initiate the cleavage of fibrillar collagen while MMP-9 (gelatinase) digests the denatured collagen fragments generated by MMP-1. The products of MMP-9 digestion are then free to be incorporated into new collagen fibrils. Elastase breaks down elastin. The expression of these enzymes is under strict control and changes as individuals age or are exposed to UV irradiation. Because MMP-1 is involved in initiation of collagen breakdown, it would be advantageous for skin care products to inhibit MMP-1 activity. In contrast, such a skin care product should not inhibit MMP-9 as this would potentially inhibit synthesis of new collagen synthesis by blocking availability of collagen building blocks. Finally, elastase should be inhibited as to prevent digestion of elastin and the resulting elasticity of the skin.

The data in Table I below gives information regarding the source and solubility for each of the samples tested. The data in Figure 5 demonstrate the effect of the samples on MMP-1 activity. Elhibin was the only sample that inhibited MMP-1. The data in Figure 6 demonstrate that most of the samples did not inhibit MMP-9. The only sample with strong inhibitory activity for MMP-9 was BVOSC ester. Finally, the data in Figure 7 demonstrate that a number of the samples inhibited elastase. These samples

were Collalift, Alphinia leaf, Elhibin, Sophorine, ACTIMP 1.3.9, Lemon and mixed citrus extracts, Kelpadelpie, Extracellium, and Colhibin.

Table I. Sample name, Supplier, Batch #, and solvent used for each sample.

Sample	Supplier	Batch #	Solvent
Collalift Malt Extract	Coletica	03020348	PBS
BVOSC Ascorbyl ester	ABG	11797RYA	DMSO/EtOH/water
CoQ10	ABG	1190LM5A	DMSO
Alpha-Lupaline	Barnet	982	DMSO
Alpinia Leaf	Barnet	010202	PBS
Sophorine	Barnet	5H636	PBS
Elhibin	Pentapharm	40197/301-02	PBS
Citrus Bioflavonoids	ABG	003-01	PBS
Lemon Bioflavonoids	ABG	1084X87A	PBS
ACTIMP 1.3.9	Barnet	105	PBS
Extracellium	Coletica	02120464	PBS
Lemon Extract	Silab	2-294-1	PBS
Kelpadelie	Unknown	104-182	PBS
Mixed Citrus Extract	Silab	2-179-2-1	PBS
Colhibin	Pentapharm	404652/325-01	PBS
BAR-TIMP	Barnet	030317	PBS

Commercially available kits were used for testing the effect of the samples on the activity of the MMPs of interest. For MMP-1, a kit from Amersham was used according to the manufacturer's specifications. For MMP-9 and Elastase, kits from Molecular Probes were used. The samples were prepared in the solvent noted in table I at stock concentrations of 100 mg/ml. The samples were diluted to 100 mg/ml using PBS.

EXAMPLE 3

Cells in skin can produce nitric oxide (NO) when exposed to UV light, and NO thus produced has the potential to induce age associated changes in skin. This study was performed in order to screen a panel of cosmetics and skin care raw materials for their effect on NO production by RAW 264.7 cells. The murine macrophage cell line RAW 264.7 was used in the study as it has been shown to produce NO when stimulated with LPS.

Murine RAW 264.7 cells were seeded in a 96 well plate at 1 X 10^5 cells /well. The plate was incubated overnight. The following day, the cells were treated with the samples at 0.001, 0.01, and 0.1% for 2 hours. The samples are listed below in Table II. Following the exposure period, LPS was added to the wells at 100 ng/ml. The plate was incubated overnight. Equal volumes of culture supernatant and Griess reagent were incubated for 15 min at room temperature and the absorbance at 540 nm was read. The amount of nitrite in the samples was calculated from a standard curve generated with sodium nitrite.

Table II. Sample description.

Sample	PD-ID	LIMS#	Solvent	Appearance
Lipochroman-6	E23D92	200300444-1	DMSO	Tannish, crystalline powder
Nutriene Tocotrienols	1999354700	200300444-2	DMSO	Brown, clear, viscous liquid
g-Tocopheryl-quinone S	00071319	200300444-3	DMSO	Brown, clear, viscous liquid
Viapure Citrus	A90/02B001	200300444-4	DMSO	Yellowish, fine powder
Soybean Zymbiosome	JQ1-124	200300444-5	Water	Clear brown liquid
NAB Pikea Robusta	46280	200300444-6	Water	Clear, yellow liquid

The data shown in Table III below and Figure 8 show that all of the samples tested had inhibitory effects on nitrite accumulation in supernatants of LPS stimulated RAW cells. The samples all had inhibitory activity.

Table III. NO production by RAW 264.7 cells stimulated with LPS. Data are shown as ng nitrite/ml supernatant.

Sample	PD-ID	LIMS#	Doses	Nitrite produced ng/ml
Negative control	NA	NA	NA	0
LPS control	NA	NA	100 ng/ml	901.7
Lipochroman-6 (L6)	E23D92	200300444-1	0.001, 0.01, 0.1 %	1006.5, 750.7, 336.7
Nutriene Tocotrienols (NT)	1999354700	200300444-2	0.001, 0.01, 0.1 %	804.1, 845.7, 504
g-Tocopherylquinone S (TQS)	00071319	200300444-3	0.001, 0.01, 0.1 %	754.2, 830.3, 217.9
Viapure Citrus (VC)	A90/02B001	200300444-4	0.001, 0.01, 0.1 %	425.4, 391.7, 294.9
Soybean Zymbiosome (SZ)	JQ1-124	200300444-5	0.02, 0.2, 2.0 %	1053.6, 834.1, 554.8
NAB Pikea Robusta (NPR)	46280	200300444-6	0.01, 0.1, 1.0 %	164, 214.9, 216.9

The results show that all of the samples had an inhibitory effect on the accumulation of nitrite in the culture supernatants. The most potent samples were lipochroman-6, Vitapure citrus, and g-tocopherylquinone S. The aqueous samples Pikea robusta and Soybean Zymbiosome both exhibited inhibitory in this experiment as they were used at higher concentrations than those used in the previous experiment. It is suspected that the high inhibitory activity seen in Pikea treated cells was due to a dilution error. Finally, it appears that the tocotrienols (NT) and synthetic tocopherol (L6) have more inhibitory activity than do mixed tocopherols

EXAMPLE 4

Four new samples that boost cellular energy were tested for their ability to augment extracellular matrix component production in response to Centella and Biodynes. Human dermal fibroblasts were used as these cells actively synthesize extracellular matrix components. In addition to measuring procollagen and elastin levels, hyaluronic acid levels were also measured. Hyaluronic acid is a member of the glycosaminoglycan family of compounds. Glycosaminoglycans make up the ground substance of connective tissue, and along with elastin, help provide elasticity to skin. They also hold water and therefore provide viscosity and hydrating properties.

Samples were diluted in media. Centella asiatica and vitamin C were prepared at 0.001%. Biodynes EMPP was prepared at 0.1%. Centella asiatica was prepared as an extract in DMSO:ethanol:water at 50:30:20. The "energy booster" samples, Seanergilium algae extract, Thiotaine, Sepitonic, and Phytovityl corn kernel extract, were all prepared in media at 0.01, 0.1, and 1.0%. Human dermal fibroblasts (Hs-27) were plated in 24 well plates and were incubated overnight. The cells were treated with the samples at the concentrations indicated for 2 consecutive days. Supernatant fluids were collected and tested for the presence of procollagen and hyaluronic acid using commercially available ELISA kits (Takara and Corgenix respectively) and elastin using the Fastin Elastin kit (Biocolor).

The levels of procollagen produced by the cells are shown in Table IV. The data demonstrate that none of the energy booster samples had a positive effect on secretion of procollagen by the cells. In contrast, the energy booster samples had no effect on or actually inhibited procollagen secretion by unstimulated and stimulated cells. The only exception was cells treated with Seanergilium produced more procollagen than untreated negative control cells

Table IV. Effect of samples on procollagen secretion. Data are expressed as ng/ml procollagen/ml supernatant calculated from a standard curve generated with the procollagen standard provided with the ELISA kit.

	Control	Centella asiatica	Biodynes EMPP	Vitamin C
Media	1533	1759	1518	1744
Seanergilium	1696	1781	1428	1325
Sepitonic	1381	1347	1297	1309
Thiotaine	1367	1347	1528	1352
Phytovityl	1221	1196	965	1055

The data in Table V show the effect of the samples on elastin secretion. An increase in Biodynes EMPP stimulated elastin secretion was seen when Sepitonic and Thiotaine were the co-stimuli. Finally, the supernatants were analyzed for the presence of hyaluronic acid. The data in Table VI show the effect of the samples on hyaluronic acid secretion by the cells. The data demonstrate that Sepitonic and Phytovityl both

augmented hyaluronic acid secretion by cells stimulated with Centella asiatica and Biodynes EMPP. In contrast, Seanergilium and Thiotaine both inhibited hyaluronic acid secretion.

Table V. Effect of samples on elastin secretion. Data are expressed as the % media control elastin calculated by dividing the amount of elastin in detected in the tissue culture supernatants from treated cells by the amount of elastin secreted by untreated control cells.

	Control	Centella asiatica	Biodynes EMPP	Vitamin C
Media	100	115	107	148
Seanergilium	107	117	111	112
Sepitonic	119	110	118	116
Thiotaine	107	107	122	112
Phytovityl	138	100	110	94

The above Table IV below shows the effect of samples on hyaluronic acid secretion. Data are expressed as ng hyaluronic acid/ml culture supernatant. The amount of hyaluronic acid in each supernatant was calculated from a standard curve generated using a hyaluronic acid standard supplied with the ELISA kit.

	Control	Centella asiatica	Biodynes EMPP	Vitamin C
Media	1112	989	862	633
Seanergilium	694	687	691	789
Sepitonic	1175	1296	1316	1226
Thiotaine	692	636	743	916
Phytovityl	1449	1205	1520	943

The most dramatic results in this experiment were the effect of some of the energy booster samples on hyaluronic acid secretion. Both Sepitonic and Phytovityl induced hyaluronic acid alone. Secretion was augmented by both Centella asiatica and

Biodynes EMPP in the presence of Sepitonic and by Biodynes EMPP in the presence of Phytovityl. Sepitonic also enhanced biodynes stimulated elasin secretion but inhibited collagen secretion. Phytovityl on the other hand inhibited both collagen and elastin secretion. Seanergilium had little effect on secretion of any of the matrix components, and Thiotaine only enhanced Biodynes stimulated elastin secretion. In conclusion therefore, due to hyaluronic acids properties of providing hydration, viscosity, and elasticity, the Sepitonic or Phytovityl materials may be valuable for skin applications where an increase in hyaluronic acid, and subsequently increased hydration, is desired.

EXAMPLE 5

Keratinocytes treated with Urlisomes and Merospheres V overnight had higher intracellular lipid levels than untreated control cells. It appeared that Urlisomes induced a higher level of lipid incorporation than did Merospheres, but this could be due to a difference in lipid concentrations of the two products. There did not seem to be any non-specific staining as visual inspection of the cells following staining, but prior to stain extraction, showed multiple intracellular lipid droplets.

Dryness can be an irritating problem with skin, and it results from loss of water from the skin. The ability to retain water is associated with lipid content of the skin, especially in the stratum corneum. Thus it seems reasonable that if the lipid content in keratinocytes, the primary cell type found in the stratum corneum, could be raised, water loss might be prevented and thus alleviate dry skin. To test this possibility, two lipid-containing samples were tested for their ability to augment the lipid levels of cultured keratinocytes.

The data from a representative experiment shown in figure 9 demonstrate that exposure of the cells to both samples resulted in increased lipid staining. Urlisomes seemed to have a greater effect on lipid levels than did Merospheres V. However, this could simply be due to a difference in lipid content of the two samples. Alternatively, the difference could result from better uptake of the lipids in the Urlisome sample compared to the Merosphere V sample.

Human HEK001 cells were plated at 2 X 10^4/well in 96 well plates and were incubated overnight. The following day, the cells were exposed to the samples that had been diluted into cell culture media at 0.005%, 0.05%, and 0.5%. The cells were then again incubated overnight. The following day, the cells were fixed in 1% formaldehyde. Cellular lipids were then stained with Oil Red O stain (1). Following staining, the lipid bound stain was extracted with isopropanol. The OD of the extracted stain was read at 515 nm.

EXAMPLE 6

[0094] The following is an example of a preferred composition according to the present invention.

Component
Octinoxate
Avobenzone
Glycerin
Panthenol
Proline

Component
Sodium Hyaluronate
Glycerin (&) Lecithin (&) Ceramide 3 (&) Beta-Sitosterol
Water (&) Rosmarinus Officinalis (Rosemary) Leaf Extract (&) Lecithin
Soybean (Glycine Soja) Protein
Hydrolyzed Rice Protein
Sunflower Seed Extract
Superoxide Dismutase
Glutathione
Tocopherol
Tocopherol Acetate
Tetrahydrodiferuloylmethane
Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract
Citrus Grandis (Grapefruit) Fruit Extract
Grape (Vitis Vinifera) Seed Extract (&) Phospholipids
D.I. Water
Glyceryl Polymethacrylate
Butylene Glycol
Potassium Cetyl Phosphate (&) Hydrogenated Palm Glycerides
Arachidyl Alcohol (&) Behenyl Alcohol (&) Arachidyl Glucoside
PEG-8 Dimethicone

Component
Hydroxyethylacrylate (&) Sodium Acryloyldimethyl Taurate Copolymer (and) Squalane (&) Polysorbate 60
Phenoxyethanol (&) Methylparaben (&) Ethylparaben (&) Propylparaben (&) Butylparaben (&) Isobutylparaben
Disodium EDTA
Phenoxyethanol (&) Iodopropynyl Butylcarbamate
Aloe Vera Gel
Bioflavonoids
C12-15 Alkyl Benzoate & Dipropylene Glycol Dibenzoate (&) PPG-15 Stearyl Ether Benzoate
Dimethicone
Tetrahexyldecyl Ascorbate
Fragrance Camomille Day 451101

EXAMPLE 6

[0095] The following is example of another composition according to the present invention.

Component
Octinoxate
Avobenzone
Glycerin

Component
Panthenol
Proline
Sodium Hyaluronate
Glycerin (&) Lecithin (&) Ceramide 3 (&) Beta-Sitosterol
Water (&) Rosmarinus Officinalis (Rosemary) Leaf Extract (&) Lecithin
Soybean (Glycine Soja) Protein
Hydrolyzed Rice Protein
Sunflower Seed Extract
Superoxide Dismutase
Glutathione
Tocopherol
Tocopherol Acetate
Tetrahydrodiferuloylmethane
Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract
Citrus Grandis (Grapefruit) Fruit Extract
Grape (Vitis Vinifera) Seed Extract (&) Phospholipids
D.I. Water
Butylene Glycol
Glyceryl Stearate (&) PEG 100 Stearate
Arachidyl Alcohol (&) Behenyl Alcohol (&) Arachidyl Glucoside
Behenyl Alcohol
Cetyl Alcohol
Ozorerite
Hydroxyethylacrylate (&) Sodium Acryloyldimethyl Taurate Copolymer (and) Squalane (&) Polysorbate 60

Component
Methylparaben
Disodium EDTA
Benzyl Alcohol
Chlorphensin
Aloe Vera Gel
Bioflavonoids
Isostearyl Palmitate
Squalane
FinSun
Caprylic/capric triglycerides
Dimethicone
Stearyl Glycyzzininate
Tetrahexyldecyl Ascorbate
Fragrance Camomille Day 451101

EXAMPLE 7

[0096] The following is also composition that can be prepared according to a further embodiment of the present invention.

Component
Glycerin
Panthenol
Proline
Sodium Hyaluronate

Component
Glycerin (&) Lecithin (&) Ceramide 3 (&) Beta-Sitosterol
Water (&) Rosmarinus Officinalis (Rosemary) Leaf Extract (&) Lecithin
Centella Asiatica
Water (&) Zea Mays (Corn) Kernel Extract
Laminaria Digitata Extract (&) Butylene Glycol
Superoxide Dismutase
Glutathione
Tocopherol
Tocopherol Acetate
Tetrahydrodiferuloylmethane
Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract
Citrus Grandis (Grapefruit) Fruit Extract
Grape (Vitis Vinifera) Seed Extract (&) Phospholipids
D.I. Water
Glyceryl Polymethacrylate
Butylene Glycol
Potassium Cetyl Phosphate (&) Hydrogenated Palm Glycerides
Arachidyl Alcohol (&) Behenyl Alcohol (&) Arachidyl Glucoside
PEG-8 Dimethicone

Component
Hydroxyethylacrylate (&) Sodium Acryloyldimethyl Taurate Copolymer (and) Squalane (&) Polysorbate 60
Phenoxyethanol (&) Methylparaben (&) Ethylparaben (&) Propylparaben (&) Butylparaben (&) Isobutylparaben
Disodium EDTA
Phenoxyethanol (&) Iodopropynyl Butylcarbamate
Bioflavonoids
C12-C15 Alkyl Ethyl Hexanote
Ubiquinone
Tetrahexyldecyl Ascorbate
Fragrance Camomille Night 451100

EXAMPLE 8

[0097] The following is an example of a further composition that can be prepared according to the present invention.

Component
Glycerin
Panthenol
Proline
Sodium Hyaluronate
Glycerin (&) Lecithin (&) Ceramide 3 (&) Beta-Sitosterol

Component
Water (&) Rosmarinus Officinalis (Rosemary) Leaf Extract (&) Lecithin
Centella Asiatica
Water (&) Zea Mays (Corn) Kernel Extract
Laminaria Digitata Extract (&) Butylene Glycol
Superoxide Dismutase
Glutathione
Tocopherol
Tocopherol Acetate
Tetrahydrodiferuloylmethane
Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract
Citrus Grandis (Grapefruit) Fruit Extract
Grape (Vitis Vinifera) Seed Extract (&) Phospholipids
D.I. Water
Butylene Glycol
Glyceryl Stearate (&) PEG 100 Stearate
Arachidyl Alcohol (&) Behenyl Alcohol (&) Arachidyl Glucoside
Behenyl Alcohol
Cetyl Alcohol
Carbomer 980
Triethanolamine
Diazolidinyl Urea (and) Iodopropynyl Butylcarbamate (Replaces R4161)
Phenoxyethanol
Aloe Vera Gel
Bioflavonoids
Isostearyl Palmitate

Component
Squalane
C12-15 Alkyl Benzoate & Dipropylene Glycol Dibenzoate (&) PPG-15 Stearyl Ether Benzoate
Caprylic/capric triglycerides
Dimethicone
Ubiquinone
Tetrahexyldecyl Ascorbate
Fragrance Camomille Night 451100

EXAMPLE 9

[0098] The following is a topical skin composition according to one embodiment of the present invention. Unless otherwise indicated, for each of the following examples, percentages are by weight.

Component	Wt. %
D.I. Water	56.595
Anti-superoxide component (superoxide dismutase)	0.005
Anti-hydrogen peroxide component (glutathione)	0.2
Anti-hydroxyl radical component (tocopheryl acetate)	1.0
Anti-hydroxyl radical component (tocopherol)	0.2
Anti-hydroxyl radical component (tetrahydrodiferuloylmethane)	0.1
Anti-hydroxyl radical component (Grape (Vitis Vinifera) Seed Extract (&) Phospholipids)	0.1
Anti-hydroxyl radical component (Bioflavonoids)	0.1
Anti-hydroxyl radical component (Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract)	0.1
Emollient(s)	21.5

Humectant(s)	5.205
Emulsifier(s)	2.3
Skin conditioning agent(s)	0.1
Sunscreen(s) (UVA)	3.0
Sunscreen(s) (UVB)	7.5
Thickener(s)	0.3
Ph modifier(s)	0.3
Preservative(s)	1.25
Fragrance(s)	0.1500
Total	100.000

EXAMPLE 10

[0099] The following is a topical skin composition according to one embodiment of the present invention. In this embodiment, the composition provides a defense against ROS and also includes components to help repair damage caused ROS.

Component	Wt. %
D.I. Water	57.635
Anti-superoxide component (superoxide dismutase)	0.005
Anti-hydrogen peroxide component (glutathione)	0.2
Anti-hydroxyl radical component (tocopheryl acetate)	1.0
Anti-hydroxyl radical component (tocopherol)	0.2
Anti-hydroxyl radical component (tetrahydrodiferuloylmethane)	0.1
Anti-hydroxyl radical component (Grape (Vitis Vinifera) Seed Extract (&) Phospholipids)	0.1
Anti-hydroxyl radical component (Bioflavonoids)	0.1
Anti-hydroxyl radical component (Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract)	0.1
Cellular activity component (retinyl acetate)	0.16
Cellular energy production component (Ubiquinone)	0.05
Collagen synthesis component (tetrahexyldecyl ascorbate)	0.1
Emollients	26.5
Humectants	5.3

Emulsifiers	2.3
Skin conditioning agent(s)	0.1
Silica (12 micron)	2.0
Silica (3 micron)	2.0
Aloe vera gel	1.0
Thickener(s)	0.3
Ph modifier(s)	0.3
Preservative(s)	0.3
Fragrance	0.150
Total	100.00

EXAMPLE 11

[00100] The following is a topical skin composition according to one embodiment of the present invention. In this embodiment, the composition provides a defense against ROS and also includes components to help repair damage caused ROS.

Component	Wt. %
D.I. Water	66.68
Anti-superoxide component (superoxide dismutase)	0.005
Anti-hydrogen peroxide component (glutathione)	0.2
Anti-hydroxyl radical component (tocopheryl acetate)	1.0
Anti-hydroxyl radical component (tocopherol)	0.2
Anti-hydroxyl radical component (tetrahydrodiferuloylmethane)	0.1
Anti-hydroxyl radical component (Grape (Vitis Vinifera) Seed Extract (&) Phospholipids)	0.1
Anti-hydroxyl radical component (Bioflavonoids)	0.1
Anti-hydroxyl radical component (Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract)	0.1
Cellular activity component (retinyl acetate)	0.16
Cellular energy production component (Ubiquinone)	0.05
Collagen synthesis component (tetrahexyldecyl ascorbate)	0.1
Emollients	1

	Humectants	1.65
	Emulsifiers	
	Skin conditioning agent(s)	0.1
	Thickener(s)	0.2
	Ph modifier(s)	
	Preservative(s)	0.3
	Fragrance	0.15
	Cyclomethicone	10.00
	Polyglycerylmethacrylate	10.00
	Dimethicone Copolyol	2.00
	12 micron Silica	2.00
	3 micron Silica	2.00
Laureth-7	Polyacrylamide (and) C_{13-14} Isoparaffin (and)	1.00
	Polysorbate 20	0.50
	Total	100.00

EXAMPLE 12

[00101] The following tests were performed to determine the effect of providing a complex composition according to the present invention in comparison to a placebo, Vitamin E, and Vitamin C. The tests were conducted by outlining a number of two inch sections on the back of a human. The following formulas were applied in a randomized manner to the sections.

	Wt. %	Wt. %	Wt. %	Wt. %
Component	A	B	C	D
Emollient(s)	21.5	21.5	21.5	21.5
Humectant(s)	6.205	6.205	6.205	6.205
Emulsifier(s)	1.3	1.3	1.3	1.3
Skin conditioning agent(s)	0.1	0.1	0.1	0.1
Thickener(s)	0.3	0.3	0.3	0.3
Ph Modifier(s)	0.3	0.3	0.3	0.3
Preservative(s)	1.25	1.25	1.25	1.25
Fragrance(s)	0.15	0.15	0.15	0.15
Tocopherol		1.2000		0.2000
Glutathione				0.2000
Tetrahydrodiferuloylmethane				0.1000
Grape (Vitis Vinifera) Seed				0.1000

Extract (&) Phospholipids				
Bioflavonoids				0.1000
Palmitoyl Hydroxypropyltrimonium Amylopectin/Glycerin Crosspolymer (and) Lecithin (and) Camellia Sinensis Extract				0.1000
Superoxide dismutase				0.0050
Sodium Hyaluronate	0.0005	0.0005	0.0005	0.0005
Ascorbic acid			10.000	
Water	QS	QS	QS	QS

[00102] After the above formulations were applied, the back was subjected to UV radiation and the skin erythema was measured.

[00103] FIGS. 1 and 2 show the results.

[00104] It should be understood that a wide range of changes and modifications could be made to the embodiments described above. It is therefore intended that the foregoing description illustrates rather than limits this invention, and that it is the following claims, including all equivalents, which define this invention.

1. A composition comprising rosemary component, lecithin, a ceramide component, a sitosterol component, glycerin, panthenol, a proline component, and a hyaluronate component.

2. A composition according to claim 1 wherein the rosemary component is a rosemary extract.

3. A composition according to claim 1 wherein the ceramide component is ceramide 3.

4. A composition according to claim 1 wherein the sitosterol component is beta-sitosterol.

5. A composition according to claim 1 wherein the hyaluronate component is sodium hyaluronate.

6. A composition according to claim 1 wherein the rosemary component is a rosemary extract, the ceramide component is ceramide 3, the sitosterol component is beta-sitosterol, and the hyaluronate component is sodium hyaluronate.

7. A composition comprising a rosemary extract and lecithin.

8. A composition comprising lecithin, ceramide 3, and beta sitosterol.

9. A method for inhibiting free radicals, reactive oxygen species, or reactive nitrogen species, comprising topically applying an effective amount of a composition comprising a rosemary component, lecithin, a ceramide component, a sitosterol component, glycerin, panthenol, a proline component, and a hyaluronate component.

FIG. 1


Maxameter - 30 Minutes Post Treatment
(Average Difference vs. Daily Baseline)
Placebo Cream
Vitamin E
Multi-Active
Vitamin C
Average Difference
Hours
0
10
20
30
40
50
60
70
80
0
12
24
36
48
60

FIG. 2


Mexameter - 10 Hours Post Treatment
(Average Difference vs. Daily Baseline)
Placebo Cream
Vitamin E
Multi-Active
Vitamin C
Average Difference
0
10
20
30
40
50
60
70
80
Hours
0
12
24
36
48
60

FIGURE 3


3000
2500
2000
1500
1000
500
0
Collagen/Viability
0.001
0.01
0.1
1
10
[Sample] %
RON SBD
Odraline
Centella
Biopept CL
EMPP
Biopept EL
Vitamin C

FIGURE 4


Elastin/Viability
2
1.5
1
0.5
0
0.001
0.01
0.1
1
10
[Sample] %
RON SBD
Odraline
Centella
Biopept CL
EMPP
Biopept EL
Vitamin C

FIGURE 5


% Control MMP-1
280.00%
240.00%
200.00%
160.00%
120.00%
80.00%
40.00%
0.00%
Collalift
BVOSC
CoQ 10
Alpha lupaline
Alpinia Leaf
Sophorine
Eihibin
Citrus
Lemon
ACTIMP1.3.9
Extracellium
Lemon ext
Kelpadelie
Mixed citrus
Colhibin
BAR-TIMP

FIGURE 6


% Control MMP-9
120.00%
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
Collalift
BVOSC
CoQ 10
Alpha lupaline
Alpinia Leaf
Sophorine
Elhibin
Citrus
Lemon
ACTIMP1.3.9
Extracellium
Lemon ext
Kelpadelie
Mixed citrus
Colhibin
BAR-TIMP

FIGURE 7


% Control Elastase
140.00%
120.00%
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
Collalift
BVOSC
CoQ 10
Alpha lupaline
Alpinia Leaf
Sophorine
Elhibin
Citrus
Lemon
ACTIMP1.3.9
Extracellium
Lemon ext
Kelpadelie
Mixed citrus
Colhibin
BAR-TIMP

FIGURE 8


120.00%
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
% Control
0.001
0.010
0.100
1.000
10.000
[Sample] %
L6
NT
TQS
VC
SZ
NPR

FIGURE 9


700.0%
600.0%
500.0%
400.0%
300.0%
200.0%
100.0%
0.0%
% Control lipids
0.005%
0.05%
0.5%
% Samples (v/v)
Urlisomes
Merospheres

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/074545

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61Q17/04 A61Q19/08 A61K8/97 A61K8/55 A61K8/67
A61K8/68 A61K8/44 A61K8/64 A61K8/63 A61K8/73
A61K8/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	"Aloe Spectrum Moisturizing Treatment Creme-Sandra Cope"[Online] 8 December 2004 (2004-12-08), XP002460049 ISSN: 1 Retrieved from the Internet: URL:http://web.archive.org/web/20041208141210/http://www.cantron.com/html/Aloe.html> [retrieved on 2007-11-27] Aloe Spectrum Moisturizing Treatment Creme- Sandra Cope- Ingredients page 1 -----	8
X	US 5 498 434 A (JOHNSTON JOHN D [US]) 12 March 1996 (1996-03-12) the whole document -----	7
	-/--	

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 December 2007	19/12/2007

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	NOPPER-JAUNKY, A

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/074545

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/034891 A (ACCESS BUSINESS GROUP INT LLC [US]; ZIMMERMAN AMY C [US]; SCIMECA JOHN) 21 April 2005 (2005-04-21) the whole document	1-9
A	CALABRESE V ET AL: "Biochemical studies of a natural antioxidant isolated from rosemary and its application in cosmetic dermatology" INTERNATIONAL JOURNAL OF TISSUE REACTIONS, BIOSCIENCE EDIPRINT, GENEVA, CH, vol. 22, no. 1, 2000, pages 5-13, XP009092509 ISSN: 0250-0868 the whole document	1-9
A	YOSHIDA Y. AND NIKI E.: "Antioxidant Effects of Phytosterol and Its Components" J.NUTR.SCI.VITAMINOL., vol. 49, 2003, pages 277-280, XP009092766 the whole document	1-9
A	PRIMAVERA G., BERARDA E.: "Clinical and instrumental evaluation of a food supplement in improving skin hydration" INTERNATION JOURNAL OF COSMETICS, vol. 27, 2005, pages 199-204, XP002460050 the whole document	1-9
A	US 6 015 548 A (SIDDIQUI MUKHTAR [US] ET AL) 18 January 2000 (2000-01-18) the whole document	1-9
A	EP 1 159 952 A (KYOWA HAKKO KOGYO CO., LTD) 5 December 2001 (2001-12-05) the whole document	1-9
A	US 5 804 168 A (MURAD H.) 8 September 1998 (1998-09-08) the whole document	1-9
A	TROMMER HAGEN ET AL: "Screening for new antioxidative compounds for topical administration using skin lipid model systems" JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, CANADIAN SOCIETY FOR PHARMACEUTICAL SCIENCES, EDMONTON, CA, vol. 8, no. 3, 2005, pages 494-506, XP009092520 ISSN: 1482-1826 the whole document	1-9

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/074545

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WEISS J.F., LANDAUER M.R.: "Protection against ionizing radiation by antioxidant nutrients and phytochemicals" TOXICOLOGY, vol. 189, 2003, pages 1-20, XP009092746 the whole document	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2007/074545

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5498434 A	12-03-1996	CA 2089920 A1	22-08-1993
		MX 9300955 A1	31-08-1994
WO 2005034891 A	21-04-2005	JP 2007508320 T	05-04-2007
		KR 20060108665 A	18-10-2006
		US 2006257386 A1	16-11-2006
US 6015548 A	18-01-2000	NONE	
EP 1159952 A	05-12-2001	AU 2824600 A	21-09-2000
		WO 0051561 A1	08-09-2000
		TW 224010 B	21-11-2004
		US 6692754 B1	17-02-2004
US 5804168 A	08-09-1998	NONE	